- Home
- RMI vs IBIO Comparison
RMI vs IBIO Comparison
Compare RMI & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$1.40
Company Overview
Basic Information| Metric | RMI | IBIO |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.3M | 83.5M |
| IPO Year | 2018 | 2009 |
Fundamental Metrics
Financial Performance| Metric | RMI | IBIO |
|---|---|---|
| Price | $15.42 | $1.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.75 |
| AVG Volume (30 Days) | 12.1K | ★ 997.3K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 73.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.71 | $0.56 |
| 52 Week High | $16.36 | $3.82 |
Technical Indicators
Market Signals| Indicator | RMI | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 41.35 | 37.72 |
| Support Level | $14.88 | $1.28 |
| Resistance Level | $15.54 | $1.80 |
| Average True Range (ATR) | 0.21 | 0.09 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 13.64 | 33.78 |
Price Performance
Historical Comparison RMI
IBIO
About RMI RiverNorth Opportunistic Municipal Income Fund Inc.
RiverNorth Opportunistic Municipal Income Fund, Inc. is a diversified, closed-end management investment company. Its investment objective is to seek current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.